Pill Identifier App

AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles

QUEBEC CITY, April 13, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today announced that it will present two abstracts outlining first in vitro data on its PI3K inhibitors as well as in vivo data on its GHRH antagonist, JMR-132, which both may potentially provide new therapeutic approaches for the treatment of cancer. These abstracts will be presented at the American Association for Cancer Research (AACR) Annual Meeting, to be held April 14-18 at the Los Angeles Convention Center in Los Angeles, California.

    Selected abstracts for poster sessions in the Exhibit Hall:


    Monday, April 16, 8:00 a.m. - 12:00 p.m. (PT)

        - Abstract #2379 "New Generation of Anilino-Substituted

          Pyridopyrazine-Urea Derivatives Show Highly Selective PI3K-

          Inhibition". Irene Seipelt, Eckhard Claus, Tilman Schuster,

          Emmanuel Polymeropoulos, Michael Teifel, Eckhard Gunther.

          The abstract reviews, for the first time, results of a preclinical

          development program on a new generation of pyridopyrazine

          derivatives which clearly indicate that these drug candidates

          selectively inhibit PI3K and could be valuable for the treatment of

          cancer.


    Tuesday, April 17, 8:00 a.m. - 12:00 p.m. (PT)

        - Abstract #3568 "GHRH-Antagonist in Combination with Docetaxel

          Chemotherapy induces regression of MX-1 human experimental breast

          cancers". Joerg B. Engel, Andrew V. Schally, Jozseph Varga, Gabor

          Halmos, Stefan Buchholz.

          The abstract reviews results which demonstrate that GHRH

          antagonist, JMR-132, inhibits doxorubicin resistant in MX-1 human

          breast cancers and induces growth arrest or total regression when

          combined with docetaxel chemotherapy. Consequently, JMR-132 could

          provide a new therapeutic approach for the treatment of early and

          metastatic breast cancer.

Copies of these abstracts are currently available and can be viewed on-line through the AACR 2007 Meeting website at: http://www.abstractsonline.com/viewer/?mkey=%7BE3F4019C%2D0A43%2D4514%2D8F66%2DB86DC90CD935%7D

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global, pure play biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

    News releases and additional information are available at

    www.aeternazentaris.com


    Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes", "anticipates", "intends", "plans", "expects", "estimates", "will," "may", "should", "approximately", and the negative or other variations of those terms or comparable terminology, are forward-looking statements. Such statements reflect management's current views, intentions, strategies and plans and are based on certain assumptions.

Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the ability of AEterna Zentaris to implement its business strategies, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of AEterna Zentaris to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.

CONTACT: Jenene Thomas, Senior Director, Investor Relations & CorporateCommunications, (418) 655-6420, ; PaulBurroughs, Media Relations, (418) 652-8525 ext. 406, jenene.thomas@aeternazentaris.com paul.burroughs@aeternazentaris.com

Ticker Symbol: (Toronto:AEZ.),(NASDAQ-NMS:AEZS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: April 2007

View comments

Hide
(web3)